Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Lirilumab: Ph I/II CA223-001 data

Data from a cohort of 29 evaluable patients with advanced platinum-refractory squamous cell carcinoma of the head and neck (SCCHN)

Read the full 203 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE